Related Experiment Video

Updated: Nov 27, 2025

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

1.1K

Split Cyclin-Dependent Kinase 4/6-Retinoblastoma 1 Axis in Pancreatic Cancer

Xing Huang1, Gang Zhang1

  • 1Zhejiang Provincial Key Laboratory of Pancreatic Disease, School of Medicine, Zhejiang University, Hangzhou, China.

Frontiers in Cell and Developmental Biology
|December 7, 2020
PubMed

Insights

Targeting cyclin-dependent kinase 4/6 (CDK4/6) shows promise for pancreatic cancer. This study reveals complexities of the CDK4/6-retinoblastoma 1 (RB1) axis, including immune involvement, for future therapeutic strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Signaling Pathways

Background:

  • Cyclin-dependent kinase 4/6 (CDK4/6)-retinoblastoma 1 (RB1) axis inhibitors are effective in various solid tumors.
  • The therapeutic role of CDK4/6-RB1 axis targeting in pancreatic cancer is not well understood.
  • Previous research suggested a tailored combination of CDK4 inhibitors for pancreatic cancer treatment, showing in vitro efficacy.

Purpose of the Study:

  • To investigate the multifaceted roles of the CDK4/6-RB1 signaling axis in pancreatic cancer.
  • To explore the impact of immune involvement and CDK6/RB1 in CDK4 inhibition-based therapies.
  • To identify novel prognostic and therapeutic targets within this pathway for pancreatic cancer.

Main Methods:

  • Analysis of pancreatic cancer patient-derived cell lines and tumor tissues.
  • In vitro studies evaluating drug efficacy and pathway modulation.
  • Investigation of immune cell interactions within the tumor microenvironment.

Main Results:

  • The CDK4/6-RB1 axis exhibits complex behavior in pancreatic cancer.
  • CDK4 inhibition demonstrated suppressive effects on pancreatic cancer cells and tissues in vitro.
  • The study identified previously overlooked aspects of immune involvement and CDK6/RB1 influence.

Conclusions:

  • The CDK4/6-RB1 axis represents a complex signaling network in pancreatic cancer.
  • Understanding these complexities, including immune interactions, is crucial for effective therapeutic targeting.
  • Further research into this axis may reveal new prognostic markers and treatment strategies for pancreatic cancer.
Keywords:
CDK4/6Rb1combination therapypancreatic cancerprecise treatmentprognosis

More Related Videos

An Orthotopic Resectional Mouse Model of Pancreatic Cancer07:17

An Orthotopic Resectional Mouse Model of Pancreatic Cancer

Published on: September 24, 2020

11.7K
Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer06:20

Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer

Published on: October 4, 2022

3.3K

Related Concept Videos

The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.2K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.8K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
37.5K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.0K